|
|
Volumn 39, Issue 3 SUPPL. 2, 2002, Pages 36-38
|
|
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
TIPIFARNIB;
ANTINEOPLASTIC AGENT;
ENZYME INHIBITOR;
FARNESYL TRANS TRANSFERASE;
TRANSFERASE;
ADULT;
AGED;
ARTICLE;
CHRONIC MYELOID LEUKEMIA;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CYTOGENETICS;
DRUG ACTIVITY;
DRUG RESPONSE;
FATIGUE;
HUMAN;
LIVER TOXICITY;
MYELODYSPLASTIC SYNDROME;
NEUTROPENIA;
PERIPHERAL NEUROPATHY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RASH;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
TREATMENT PLANNING;
BLOOD DISEASE;
DRUG ANTAGONISM;
GENETICS;
REVIEW;
ALKYL AND ARYL TRANSFERASES;
ANTINEOPLASTIC AGENTS;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
HEMATOLOGIC NEOPLASMS;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
MYELODYSPLASTIC SYNDROMES;
TREATMENT OUTCOME;
|
|
EID: 0036655776
PISSN: 00371963
EISSN: None
Source Type: Journal
DOI: 10.1053/shem.2002.35986 Document Type: Article |
|
Times cited : (5)
|
|
References (7)
|
